Answers are grounded in this paper and cite their sources.
Metabolic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and the metabolic dysfunction and alcohol-associated liver disease (MetALD) phenotype, are major causes of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Circular RNAs (circRNAs) are covalently closed RNA molecules generated mainly by back-splicing or, in selected cases, by read-through transcription followed by circularization. Their resistance to exonuclease degradation, context-specific expression, and enrichment in extracellular vesicles (EVs) make them attractive candidates for mechanistic discovery, liquid-biopsy biomarker development, and RNA-targeted therapy. Here, we review current evidence on circRNA biogenesis and mechanisms of action in metabolic liver diseases, with emphasis on MASLD/MASH, ALD/MetALD-related fibrosis, cirrhosis, and HCC. In MASLD/MASH, circRNAs have been implicated in nutrient-response signaling, lipid handling, mitochondrial stress, autophagy, inflammatory amplification, macrophage polarization, and hepatic stellate cell (HSC) activation. In ALD and MetALD, direct MetALD-specific circRNA evidence remains limited; available data mainly support ethanol-induced hepatic circRNA remodeling, macrophage inflammatory responses, and apoptosis. Fibrosis-associated circRNAs connect inflammatory and transforming growth factor β (TGF-β)-centered signaling to extracellular matrix remodeling, whereas HCC currently provides the strongest near-term biomarker opportunity, particularly through circulating and exosomal circRNAs that may complement alpha-fetoprotein (AFP). However, most candidate mechanisms and biomarker signatures remain discovery-stage findings that require circRNA-specific validation, etiology-specific cohorts, clinically relevant comparator groups, and standardized assays. Overall, circRNAs should be viewed not only as microRNA (miRNA) sponges but also as multifaceted regulators of RNA-binding protein (RBP) interactions, organelle function, translation, EV-mediated signaling, disease endotyping, and therapeutic response. Clinical translation will require standardized detection methods, multicenter longitudinal validation, pharmacokinetic and pharmacodynamic evaluation, and liver-cell-specific delivery strategies.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.